Diabetes beyond insulin: Review of new drugs for treatment of diabetes mellitus

Current Drug Discovery Technologies

Volumn 4, Issue 1, 2007, Pages 39-47

  Modi, Pankaj ^a  

^a Innovatech Rx   (Canada)

Author keywords

Biguanides; Diabetes mellitus (DM); Glucosidase inhibitors; HbA1c; Incretin; Insulin secretagogues; Meglitinide analogues; Thiazolidinediones; Type 1 diabetes; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; CHLORPROPAMIDE; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; RIOMET; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANOREXIA; BLOATING; DIARRHEA; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC PRECONDITIONING; LACTIC ACIDOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADMINISTRATION, INHALATION; BENZAMIDES; BENZOIC ACIDS; BIGUANIDES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASES; DRUG THERAPY, COMBINATION; GLUCOSIDASES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34447136762     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016307781115476     Document Type: Review

References (66)

1. American Diabetes Association, Standard of medical care in diabetes. Diabetes Care 29: S4-S42 (2006).
2. Institute for Clinical Systems Improvement (ICSI) Management of type 2 diabetes mellitus, Bloomington, Minnesota Institute for Clinical Systems Improvement (ICSI) pp. 79 (2005).
3. Davies M.J., Tringham J.R., Troughton J., Khunti K.K.: Prevention of type 2 diabetes mellitus, A review of the evidence and its application in a UK setting. Diabet. Med. 21: 403-14 (2004).
4. American Diabetes Association, Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 26 (suppl 1), S28 -S32, (2003).
5. IDF Clinical Guidelines Task Force, Global guideline for Type 2 diabetes. International Diabetes Federation Conference, Brussels, (2005).
6. Wickersham R.M., Novak K.K., Eds.; Drug Facts and Comparisons; Wolter Kluwer: St. Louis, Montana, (2006).
7. Average wholesale prices. www.drugstore.com/pharmacy/drugindex: Accessed June 4, (2007).
8. Epocrates Drug Database. www2.epocrates.com/index.html.: (2007).
9. Turner R.C., Cull C.A., Frighi V., Avery L.: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus, progressive requirement for multiple therapies (UKPDS 40). JAMA 281, 2005-2012, (1999).
10. Inzucchi SE.: Oral antihyperglycemic therapy for type 2 diabetes. JAMA 287, 360-372, (2002).
11. Klam Cheri, Neher Jon, Mayo Helen.: What is the best medical therapy for new-onset Type-2 diabetes?J. Fam. Pract. 55(11), 998-1000, (2006).
12. Renee R.K.: Practical Review of Oral Antihyperglycemic Agents for Type 2 Diabetes Mellitus. Diabetes Educ. 32(6) 869-876, (2006).
13. DeFronzo R.A.: Pharmacologic therapy for type 2 diabetes mellitus, Ann. Intern. Med. 131(4), 281-303, (1999).
14. Bryan J., Crane A., Vila-Carriles W.H., Babenko A.P., Aguilar-Bryan L.: Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels. Curr. Pharma. Design 21 (11), 2699-2716, (2005).
15. Bloomgarden Z.T.: New Therapeutic Approaches To Non-Insulin-Dependent Diabetes Mellitus. Endocrine Practice 5(3), 307-312, (1997).
16. KAD R.D.: Mitiglinide. Drugs (5)98-101, (2004).
17. Phillips L.S., Dunning BE.: Nateglinide (Starlix™), Update on a new antihyperglycemic agent. Int. J. Clin. Pract. 57, 535 -541, (2003).
18. Dornhorst A.: Insulinotropic meglitinide analogue. Lancet 358, 1709-1716, (2001).
19. Prandin.: Physicians' Desk Reference [electronic version], Thomson Micromedex: Colorado, (2006).
20. Starlix.: Physicians' Desk Reference [electronic version]. Thomson Micromedex: Colorado, (2006).
21. Caulfield M., O'Brien K.: Cardiovascular Safety of Oral Antidiabetic Agents, The Insulin Secretagogues. Clinical Diabetes 20, 81-84, (2002).
22. Saenz A., Fernandez-Esteban I., Mataix A., Ausejo M., Roque M., Moher D.: Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst. Rev. (3) (2005).
23. UK Prospective Diabetes Study (UKPDS) Group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 352, 854-865, (1998).
24. Saenz A., Fernandez-Esteban I., Mataix A.: Metformin monotherapy for type 2 diabetes mellitus, Cochrane Metabolic and Endocrine Disorders Group. Cochrane Database Syst. Rev. (3) (2005).
25. Wulffele M.G., Kooy A., De Zeeuw D.: The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review. J. Intern. Med. (256)1 (2004).
26. Johnson J.A., Simpson S.H., Toth E.L.: Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet. Med. (22)497-502, (2005).
27. Kirpichnikov D., McFarlane SI., Sowers J.R.: Metformin, an update. Ann. Intern. Med. 137, 25-33, (2002).
28. Salpeter S.R., Greyber E., Pasternak G.A.: Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Arch. Intern. Med. 163, 2594-2602, (2003).
29. Glucophage. Physicians' Desk Reference [electronic version]. Thomson Micromedex: Colorado, (2006).
30. Shimabukuro M., Zhou Y-T., Lee Y.: Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J. Biol. Chem. (273)3547-3550, (1998).
31. Chiquette E., Ramirez G., DeFronzo R.: A metaanalysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch. Intern. Med. 164, 2097-2104, (2004).
32. Ahmann A.J., Riddle M.C.: Current oral agents for type 2 diabetes; many options, but which one to choose when? Postgrad. Med. 111, 32-46, (2002).
33. Dormandy J.A., Charbonnel B., Eckland D.J.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 366, 1279-1289, (2005).
34. Choi D., Kim S.K., Choi S.H.: Preventative effects of Rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 27, 2654-2660, (2004).
35. Nesto R.W., Bell D., Bonow R.O.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 27, 256 -263, (2004).
36. Glitazone-associated macular edema. Pharmacist's Letter/Prescriber's Letter 22, 220-205, (2006).
37. Effect of Rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. The DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Lancet 368, 666, (2006).
38. Scheen A.J.: Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf. 24, 873-888, (2001).
39. Avandia.: Physicians' Desk Reference [electronic version], Thomson Micromedex, (2006).
40. Actos.: Physicians' Desk Reference [electronic version], Thomson Micromedex; (2006).
41. Van de Laar F.A., Lucassen P.L.B.J., Akkermans R.P., Van de Lisdonk E.H., Rutten G.E.H.M., Can W.C.: Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane. Database Syst. Rev. 2, (2005).
42. Van der Laar F.A., Lucassen P.L.B.J., Akkermans R.P.: Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Metabolic and Endocrine Disorders Group, Cochrane Database Syst. Rev. 2, (2005).
43. Precose.: Physicians' Desk Reference [electronic version]. Thomson Micromedex, (2006).
44. Glyset.: Physicians' Desk Reference [electronic version]. Thomson Micromedex, (2006).
45. Yamanouchi T., Sakai T., Igarashi K., Ichiyanagi K., Watanabe H., Kawasaki T.: Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed Type 2 diabetes. Diabet. Med. 22, 980-985, (2005)
46. Browne D.L., Avery L., Turner B.C.: What do patients with diabetes know about their tablets? Diabet. Med. 17, 528 -531, (2000).
47. DeFronzo R.A., Bergenstal R.M., Cefalu W.T.: Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise. Diabetes Care 28, 1922-1928, (2005).
48. Defronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D.: Effects of exenatide(exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28(5), 1092-100, (2005).
49. Calara F., Taylor K., Han J., Zabala E., Carr E.M., Wintle M., Fineman M.: A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin. Ther. 27(2), 210-215, (2005).
50. Nauck M.A., Meier J.J.: Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul. Pept. 128(2), 135-48, (2005).
51. Gedulin B.R., Nikoulina S.E., Smith P.A., Gedulin G., Nielsen L.L., Baron A.D., Parkes D.G., Young A.A.: Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight. Endocrinology 146(4), 2069-76, (2005).
52. Young A.: Selected Studies About Symli. Adva Pharmacol. 52, 289-320, (2005).
53. Ryan G.J., Jobe L.J., Martin R.: Symlin. Clin. Ther. 27 (10), 1500-12 (2005).
54. Diabetes in Control Com, News and Information for Medical Professionals Issue #300, (2006).
55. FDA accepts Merck's first in class drug application for JANUVIA for type 2. Available at: www.diabetes@topica.email-publisher.com, February 22, (2006).
56. Perfetti R., D'Amico E.: Rational drug design and PPAR agonists. Curr. Diabetes Rep. 5, 340-345 (2005).
57. Nielsen L.L.: Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. D.D.T, 10, 703-710, (2005).
58. Sarabu R., Grimsby J.: Targeting glucokinase activation for the treatment of type 2 diabetes - a status review. Curr. Opin. Drug. Discov. Devel. 8, 631-637 (2005).
59. Campbell R.K., Campbell L.K., White J.R.: Insulin lispro: its role in the treatment of diabetes mellitus. Ann. Pharmacother. 30, 1263-71, (1996).
60. Galloway J.A.: New directions in drug development: mixtures, analogues, and modeling. Diabetes Care 16(3), S16-S23, (1993).
61. Howey D.C., Bowsher R.R., Brunelle R.L., Woodworth J.R.: [Lys(B28), Pro(B29)]-human insulin, A rapidly absorbed analogue of human insulin. Diabetes 43, 396-402, (1994).
62. Torlone E., Fanelli C., Rambotti A.M., Kassi G., Modarelli F., Di Vincenzo A.: Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37, 713-20, (1994).
63. Johnson M.D., White J.R., Campbell R.K.: Insulin therapy in the era of insulin analogs. U.S. Pharmacist 21, HS35-HS44, (1996).
64. Schubert-Zsilavecz M., Wurglics M.: Better blood sugar control in diabetics, Insulin glargin - a long-acting insulin analogue. Pharm. Unserer. Zeit. 30(2), 125-30, (2001).
65. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., Perriello G., Bolli G.B.: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. (21)11, 1213-1220, (2004).
66. Efendic S., Portwood N.: Overview of incretin hormones. Horm. Metab. Res. 36, 742-746, (2004).